Jaguar Health (JAGX)

Its main commercial focus is Mytesi, the brand name for crofelemer, an oral therapy approved in the United States for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS who are receiving antiretroviral therapy. This positions Jaguar Health in a specialized area of supportive care, where chronic diarrhea can affect adherence to treatment, quality of life, and daily functioning. The company’s human health business generates the majority of revenue and remains central to its strategy.

Jaguar Health also pursues development programs aimed at other diarrhea-related and overactive bowel conditions, including urgency, bowel incontinence, and chronic debilitating diarrhea associated with different underlying causes. These programs reflect the company’s broader effort to build a gastrointestinal pipeline around the properties of crofelemer and related plant-based technologies.

In addition to human therapeutics, Jaguar Health has an animal health segment that develops and commercializes gastrointestinal products for companion and production animals. This gives the company a dual-market structure, although its public-market profile is largely tied to the performance of Mytesi and the progress of its human pharmaceutical pipeline. Jaguar Health’s distinctive positioning comes from combining botanical drug development, gastrointestinal specialization, and a commercial product already approved for a defined medical need.